Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan Combined With Head Radiotherapy for Brain Metastases From Her2-negative Breast Cancer
NCT06462079Phase 2Not yet recruiting
- Sponsor
- Guangzhou Medical University
- Start
- Jun 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of sacituzumab govitecan in breast cancer, sponsored by Guangzhou Medical University. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06462079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462079.